IFRX Stock Analysis: Buy, Sell, or Hold?
IFRX - InflaRx N.V. Common Stock
$2.06
-0.11 (-5.07%)
▼
5d:
-19.53%
30d:
-3.29%
90d:
+125.04%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When IFRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called IFRX this week
0% bullish • 2 bearish
0% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IFRX is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IFRX is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IFRX is currently trading at $2.06, which is considered oversold relative to its 30-day fair value range of $2.03 to $2.60.
Technical Outlook: Technically, IFRX is in a strong uptrend. The price is currently testing key support at $2.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.91 (+284.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IFRX is in a strong uptrend. The price is currently testing key support at $2.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.91 (+284.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.03 -
$2.60
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 284.0% below Wall St target ($7.91)
- WARNING: Recommendation downgraded due to -19.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.03 -
$2.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.03
Resistance Level
$2.94
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.51
Wall Street Target
$7.91
(+284.0%)
Revenue Growth (YoY)
-80.8%
Share & Embed Analysis
Last updated: June 03, 2026 7:47 PM ET
Data refreshes hourly during market hours. Next update: 8:47 PM
Data refreshes hourly during market hours. Next update: 8:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IFRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
